<DOC>
	<DOCNO>NCT02354690</DOCNO>
	<brief_summary>Background : Adoptive T cell therapy tumor infiltrate lymphocyte ( TILs ) report induce durable clinical response patient metastatic melanoma . From patient tumor material T cell extract , expand activate vitro 4-6 week culture period . Before TIL infusion patient precondition lymphodepleting chemotherapeutic regimen . After TIL infusion , patient treat IL-2 support T cell activation expansion vivo . The BRAF inhibitor approve treatment metastatic melanoma function selectively inhibit BRAF mutate enzyme , consequently halt proliferation tumor cell . Furthermore , vitro test show vemurafenib immunomodulatory effect hypothesize synergize TIL therapy , confirm animal study . Objectives : - To evaluate safety feasibility combine vemurafenib ACT TILs . - To evaluate treatment relate immune response - To evaluate clinical efficacy Design : - Patients screen physical exam , medical history , blood sample ECG . - Patients start vemurafenib 960 mg BID continue TIL preparation . - 7 day start vemurafenib , patient undergo surgery harvest tumor material TIL production . - Patient stop vemurafenib admit day -8 order undergo lymphodepleting chemotherapy cyclophosphamide fludara start day -7 . - On day 0 patient receive TIL infusion shortly start IL-2 infusion continually follow decrescendo regimen . - The patient follow progression 5 year .</brief_summary>
	<brief_title>Vemurafenib TIL Therapy Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Histologically confirm unresectable stage III stage IV metastatic melanoma . Metastasis available surgical resection ( 2 cm3 ) residual measureable disease resection . Pathologically verify BRAF mutation . ECOG performance status 01 . Life expectancy ≥ 3 month . No significant toxicity ( CTC ≤ 1 ) prior treatment . Adequate renal , hepatic hematologic function . Women childbearing potential ( WOCBP ) men sexual relationship WOCBP must use effective method contraception treatment least 6 month completion treatment . Able comprehend information give willing sign inform consent . Other malignancy , unless follow ≥ 5 year sign disease , except squamous cell carcinoma adequately treat carcinoma situ colli uterus . Cerebral metastasis . Patients previously treat CNS metastasis participate surgically remove treated stereotactic radiotherapy stable &gt; 28 day treatment measure MRI . Patients asymptomatic untreated CNS metastasis participate base investigator evaluation . Patients ocular melanoma . Previous treatment BRAF inhibitor . Severe allergy , history anaphylaxis know allergy drug administer . Serious medical psychiatric comorbidity . QTc ≥ 450 ms. Clearance &lt; 70 ml/min . Acute chronic infection e.g . HIV , hepatitis , tuberculosis Active autoimmune disease . Pregnant og nursing woman . Need immunosuppressive treatment , e.g . corticosteroid methotrexate . Concomitant treatment experimental drug . Patients uncontrolled hypercalcemia More four week must elapse since prior systemic therapy time treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>